Skip to NavigationSkip to content

AnaptysBio's etokimab fails in moderate-to-severe atopic dermatitis

Published on 11/11/19 at 11:03am

AnaptysBio has announced disappointing new Phase 2b data for its anti-IL-33 candidate etokimab in the treatment of moderate-to-severe atopic dermatitis.

The company revealed that, in a study of 300 adult participants, the drug had failed to show superior benefit in the treatment of the condition according to the Eczema Area and Severity Index (EASI) after 16 weeks of treatment compared to placebo, falling short of the trial’s primary endpoint.

“We are surprised and very disappointed by the topline results of the ATLAS trial,” said Hamza Suria, President and Chief Executive Officer of AnaptysBio. “We would like to thank all involved in the participation and support of the ATLAS study, including the patients, the investigators, their staff and our employees.  We look forward to continuing our strategy of advancing our wholly-owned clinical and preclinical pipeline programmes.”

The news has led AnaptysBio to halt another Phase 2b trial investigating the drug in the treatment of eosinophilic asthma in around 400 patients. However, the company confirmed that another trial, investigating around the drug’s efficacy in approximately 100 participants with chronic rhinosinusitis with nasal polyps will continue, with interim analysis results expected in the first quarter of 2020.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches